Conclusion
dyslipidemia, cancer, cardiometabolic, ALL
CANCER, DYSLIPIDEMIA
These findings support the use of omega-3 fatty acids to reduce some adverse cardiometabolic and inflammatory risk factors in children with ALL. Our findings show that an ω3-LCPUFA intervention is feasible, and the results suggest that ω3-LCPUFA supplementation in these patients could help prevent, delay, and/or mitigate the development of dyslipidemia and cardiometabolic conditions that can have a negative impact on them. It is unknown if the effect of omega-3 may last longer than 3 months. We consider that large-scale trials are needed in children with cancer to confirm these results.